Repurposing of the RIPK1-Selective Benzo[1,4]oxazepin-4-one Scaffold for the Development of a Type III LIMK1/2 Inhibitor
Year: 2025
Type: article
Abstract: High Resolution Image Download MS PowerPoint Slide Benzoxazepinones have been extensively studied as exclusively selective RIP kinase 1 inhibitors. This scaffold binds to an allosteric pocket created by an αC-out/DFG-out conformation. This inactive conformation results in a large expansion of the kinase back pocket, a conformation that has also been reported for LIM kinases. Scaffold hopping is common in the design of orthosteric kinase inhibitors but has not been explored in the design of allosteric inhibitors, mainly due to the typically exclusive selectivity of type III inhibitors. Here, we hypothesized that the shared structural properties of LIMKs and RIPKs could lead to novel type III LIMK inhibitors using the benzoxazepinone scaffold. We report the discovery of a novel LIMK1/2 inhibitor that relies on this scaffold-based approach. The discovered compound 10 showed low nanomolar potency on LIMK1/2 and exceptional selectivity, as confirmed by a comprehensive selectivity panel with residual RIPK activity as the only off-target. The study provides one of the few examples for scaffold hopping for allosteric inhibitors, which are usually associated with exclusive target selectivity.
Source: ACS Chemical Biology
Authors: Sebastian Mandel, Thomas Hanke, Sebastian Mathea, Deep Chatterjee, Hayuningbudi Saraswati, Benedict-Tilman Berger, Martin Peter Schwalm, Satoshi Yamamoto, Michiko Tawada, Terufumi Takagi, Mahmood Ahmed, Sandra Röhm, Ana Corrionero, Patricia Alfonso, Maria Baena, Lewis Elson, Amelie Menge, Andreas Krämer, Raquel Pereira, Susanne Müller, Daniela S. Krause, Stefan Knapp
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
Funders: Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Bayer, Takeda Pharmaceutical Company, McGill University, Deutsches Krebsforschungszentrum, Genome Canada, Ontario Genomics, European Federation of Pharmaceutical Industries and Associations, Ontario Genomics Institute, Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, Innovative Medicines Initiative, Deutschen Konsortium für Translationale Krebsforschung, Genentech, Janssen Biotech, Structural Genomics Consortium
OpenAlex ID: W4409414898
